Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer

Acta Oncologica

Volumn 44, Issue 7, 2005, Pages 742-747

  Salminen, Eeva ^a   Ala Houhala, M ^a   Korpela, J ^a   Varpula, M ^a   Tiitinen, S L ^b   Halleen, J M ^b   Vaananen H K ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TARTRATE RESISTANT ACID PHOSPHATASE 5B; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; BONE RESORPTION; CROSS-SECTIONAL STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 27544492528     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500327586     Document Type: Article

References (21)

1. Cancer Incidence in Finland. Finnish Cancer Registry, Helsinki 2000.
2. Budendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000;31:578-83.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
4. Oefelein MG, Ricchuiti V, Conrad W, Seffel A, Bodner D, Goldman R, et al. Skeletal fractures associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patient with prostate cancer. J Urol 2001; 166:1724-8.
5. Salminen EK, Portin R, Korpela J, Helenius H, Parvinen L-M, Backman H, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003;89:971-6.
6. Rodan GA. The development and function of the skeleton and bonemetastases. Cancer 2003;97:726-32.
7. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Yam LT. Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta 2002;326:113-22.
8. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111:783-91.
9. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001;47:597-600.
10. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004;34:187-94.
11. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaatanen HK. Tartrate resistant acid phosphatase 5B: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-45.
12. Eastham JA. Bishosphanates and prostate cancer: Maintaining bone integrity and quality of life. Am J Urol Review 2004;2(Suppl 2):5-8.
13. Tu SM, Millikan RE, Mengistu B, Delpassand SE, Amato RJ, Pagliaro LC. Bone targeted therapy for advanced androgen.independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001;357:336-41.
14. Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000;48: 1443-6.
15. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439.
16. Shahinian V, Kuo Y-F, Freeman J, Goodwin J. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.
17. Oeflein MG, Ricchiuti M, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. Am J Urol Rev 2004;2(Suppl 2): 16-20.
18. Tamada D, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastatses of patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001;19:45-51.
19. Morote J, M'hammed YI, Martinez E, Esquena S, Lorente JA, Gelabert A. Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. Urology 2002;59:277-80.
20. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005;103:237-41.
21. Green JR. Skeletal complications of Prostate Cancer: Pathophysiology and Therapeutic Potential of Bisphosphonates. Acta Oncol 2005;44:284-94.